 Home > Active Ingredient News > Blood System > Breakthrough in relapsed AML therapy: Golden Biotech reports on the progress of Antroquinonol's trial

Breakthrough in relapsed AML therapy: Golden Biotech reports on the progress of Antroquinonol's trial

 Last Update: 2020-12-16
 Source: Internet
 Author: User

Tags

pepcid drug class

finasteride drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Golden Biotechnology, Taiwan's leading biopharmaceutical company, recently announced that its new drug, Antroquinonol (Hocena), is superior to other drugs listed in Phase II clinical trials for treatable relapsed AML (acute myeloid leukemia).
results show that Antroquinonol has a higher mitigation rate (CR / Cri s 50%) and survival rate.
this makes it possible to treat monotherapy without the need for high-security therapies with combined chemotherapy.
new drug, Antroquinonol, was named the FDA's AML Orphan Drug (ODD) in 2015.
endpoints showed that the total remission rate (CR /CRi) was 50% in patients with relapsed acute myeloid leukemia.
this is higher than the CR/CRi range (21% to 33%) of other drugs listed in the second phase of the trial.
treatment, the count of abnormal maternal cells in bone marrow or blood in 80% of patients decreased to less than 5%.
for secondary endpoints, the total survival rate of patients with relapsed AML reached 100% by the 6th month after treatment, which increased the likelihood of a bone marrow transplant.
addition, 90 percent of patients do not need a blood transfusion during treatment with Antroquinonol (Hocena).
oral treatment and reduced blood transfusions significantly improved the quality of life of AML patients.
no significant side effects (SAEs) occurred during the 6-month treatment period.
。

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Atipamezole hydrochloride 104075-48-1 reduce sedation lower blood pressure

CAS No.: 104075-48-1

Pharm grade

$1/G EXW

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.